Horizon Therapeutics plc Submits Teprotumumab Biologics License Application (BLA) for the Treatment of Active Thyroid Eye Disease (TED)
DUBLIN--(BUSINESS WIRE)--Horizon submitted a BLA to the U.S. FDA for its investigational medicine teprotumumab for the treatment of active thyroid eye disease.